FI971171A0 - Koostumukset ja menetelmät syöttösolujen välittämien tulehdussairauksien hoitamiseksi - Google Patents

Koostumukset ja menetelmät syöttösolujen välittämien tulehdussairauksien hoitamiseksi

Info

Publication number
FI971171A0
FI971171A0 FI971171A FI971171A FI971171A0 FI 971171 A0 FI971171 A0 FI 971171A0 FI 971171 A FI971171 A FI 971171A FI 971171 A FI971171 A FI 971171A FI 971171 A0 FI971171 A0 FI 971171A0
Authority
FI
Finland
Prior art keywords
compositions
treatment
methods
inflammatory diseases
mast cell
Prior art date
Application number
FI971171A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971171A (fi
Inventor
Ken D Rice
Jeffrey M Dener
Anthony R Gangloff
Elaine Yee-Lin Kuo
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of FI971171A0 publication Critical patent/FI971171A0/fi
Publication of FI971171A publication Critical patent/FI971171A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
FI971171A 1994-09-23 1997-03-20 Koostumukset ja menetelmät syöttösolujen välittämien tulehdussairauksien hoitamiseksi FI971171A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31226994A 1994-09-23 1994-09-23
PCT/US1995/011814 WO1996009297A1 (fr) 1994-09-23 1995-09-14 Compositions et procedes de traitement de maladies inflammatoires provoquees par les mastocytes

Publications (2)

Publication Number Publication Date
FI971171A0 true FI971171A0 (fi) 1997-03-20
FI971171A FI971171A (fi) 1997-03-20

Family

ID=23210670

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971171A FI971171A (fi) 1994-09-23 1997-03-20 Koostumukset ja menetelmät syöttösolujen välittämien tulehdussairauksien hoitamiseksi

Country Status (25)

Country Link
US (2) US6022969A (fr)
EP (1) EP0782571A1 (fr)
JP (1) JPH10506390A (fr)
KR (1) KR970706267A (fr)
CN (1) CN1160398A (fr)
AU (1) AU694275B2 (fr)
CA (1) CA2200561A1 (fr)
CZ (1) CZ87097A3 (fr)
EE (1) EE03525B1 (fr)
FI (1) FI971171A (fr)
HR (1) HRP950499B1 (fr)
HU (1) HUT77770A (fr)
IL (1) IL115405A (fr)
LT (1) LT4234B (fr)
LV (1) LV11865B (fr)
MX (1) MX9702125A (fr)
NO (1) NO309605B1 (fr)
NZ (1) NZ294392A (fr)
PL (1) PL183552B1 (fr)
RU (1) RU2159229C2 (fr)
SI (1) SI9520101A (fr)
SK (1) SK37997A3 (fr)
TW (1) TW442478B (fr)
WO (1) WO1996009297A1 (fr)
ZA (1) ZA958028B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000029679A (ko) * 1996-07-30 2000-05-25 헤이즈 더블유.그쉬웬드 다니엘 에이치.페트리 트립타아제활성관련질병을치료하기위한화합물및조성물
US5968782A (en) * 1996-12-04 1999-10-19 Brigham And Womens's Hospital, Inc. Mast cell protease that cleaves fibrinogen
WO1998033812A1 (fr) * 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Inhibiteurs peptidiques des proteases de mastocytes
AU8997498A (en) * 1997-09-05 1999-03-29 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitor
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
AU1208999A (en) * 1997-11-10 1999-05-31 Array Biopharma, Inc. Compounds which inhibit tryptase activity
JP2002502850A (ja) * 1998-02-06 2002-01-29 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ トリプターゼ阻害物質
AU2723099A (en) 1998-02-06 1999-08-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
WO2000014097A2 (fr) * 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouvelles pyranoses
US6362216B1 (en) 1998-10-27 2002-03-26 Array Biopharma Inc. Compounds which inhibit tryptase activity
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
US6673786B1 (en) 1999-08-10 2004-01-06 Altana Pharma Ag Tryptase inhibitors
JP2003509417A (ja) * 1999-09-14 2003-03-11 アルタナ ファルマ アクチエンゲゼルシャフト トリプターゼインヒビター
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
AU1413301A (en) * 1999-11-17 2001-05-30 Sumitomo Pharmaceuticals Company, Limited Diabetic remedy containing dipiperazine derivative
TR200402164T4 (tr) 1999-12-20 2004-10-21 Altana Pharma Ag Triptaz inhibitörler
US7015325B2 (en) * 1999-12-20 2006-03-21 Altana Pharma Ag Tryptase inhibitors
WO2001052883A1 (fr) * 2000-01-20 2001-07-26 Amgen Inc. Inhibiteurs du recepteur-2 active par une protease (par-2) utilises comme nouveaux agents therapeutiques contre l'asthme
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
CA2438594A1 (fr) * 2001-01-31 2002-08-08 Altana Pharma Ag Derives de diazocine et leur utilisation en tant qu'inhibiteurs de tryptase
CA2438685A1 (fr) 2001-02-21 2002-08-29 Altana Pharma Ag Inhibiteurs de tryptase
WO2002066420A2 (fr) * 2001-02-21 2002-08-29 Altana Pharma Ag Inhibiteurs de la tryptase
EP1370518A2 (fr) * 2001-03-15 2003-12-17 ALTANA Pharma AG Inhibiteurs de la tryptase
WO2002074732A2 (fr) * 2001-03-15 2002-09-26 Altana Pharma Ag Inhibiteurs de la tryptase
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
ATE348803T1 (de) 2001-06-19 2007-01-15 Altana Pharma Ag Tryptase-inhibitoren
JP2005523883A (ja) * 2001-12-13 2005-08-11 興和株式会社 遅延型過敏症予防・治療用医薬組成物
WO2003075853A2 (fr) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Derives cycliques servant de modulateurs de l'activite du recepteur de la chimiokine
TW200524849A (en) * 2003-07-02 2005-08-01 Hoffmann La Roche Hydroxyalkylamide derivatives
US20050255154A1 (en) * 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
TW200815351A (en) * 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
TWI414527B (zh) * 2010-10-06 2013-11-11 Ind Tech Res Inst 異山梨糖醇衍生物及包含該衍生物之液晶顯示器
CN102453037B (zh) * 2010-10-25 2014-06-25 财团法人工业技术研究院 异山梨糖醇衍生物及包含该衍生物的液晶显示器

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4746737A (en) * 1985-07-26 1988-05-24 Kowa Co., Ltd. Phenyl guanidinobenzoate derivatives which have protease inhibitory activity
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
UA42719C2 (uk) * 1993-03-12 2001-11-15 Аксіз Фармасьютікелз, Інк Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
JPH10501238A (ja) * 1994-06-01 1998-02-03 アリス ファーマシューティカル コーポレイション 肥満細胞媒介症状を治療するための組成物及び方法

Also Published As

Publication number Publication date
CN1160398A (zh) 1997-09-24
HRP950499A2 (en) 1997-08-31
EE03525B1 (et) 2001-10-15
JPH10506390A (ja) 1998-06-23
CA2200561A1 (fr) 1996-03-28
IL115405A0 (en) 1995-12-31
CZ87097A3 (en) 1997-11-12
TW442478B (en) 2001-06-23
EE9700089A (et) 1997-10-15
MX9702125A (es) 1998-04-30
US6022969A (en) 2000-02-08
WO1996009297A1 (fr) 1996-03-28
IL115405A (en) 2002-07-25
AU694275B2 (en) 1998-07-16
LT97065A (en) 1997-08-25
SI9520101A (en) 1997-12-31
NO309605B1 (no) 2001-02-26
RU2159229C2 (ru) 2000-11-20
HRP950499B1 (en) 2003-04-30
ZA958028B (en) 1996-04-18
PL183552B1 (pl) 2002-06-28
LT4234B (en) 1997-10-27
EP0782571A1 (fr) 1997-07-09
KR970706267A (ko) 1997-11-03
NO971305L (no) 1997-05-06
NZ294392A (en) 1999-05-28
AU3718095A (en) 1996-04-09
PL319587A1 (en) 1997-08-18
NO971305D0 (no) 1997-03-20
US6211228B1 (en) 2001-04-03
FI971171A (fi) 1997-03-20
HUT77770A (hu) 1998-08-28
LV11865A (lv) 1997-10-20
SK37997A3 (en) 1998-12-02
LV11865B (en) 1998-01-20

Similar Documents

Publication Publication Date Title
FI971171A0 (fi) Koostumukset ja menetelmät syöttösolujen välittämien tulehdussairauksien hoitamiseksi
FI971969A (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
FI970918A0 (fi) Yhdisteet ja menetelmät syövän hoitamiseksi
NO995095L (no) Substituerte imidazoler nyttig ved behandlingen av inflammasjonssykdommer
FI956242A (fi) Solukytkin ja menetelmä solujen reitittämiseksi sen kautta
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
KR100344712B1 (ko) 알러지성및염증성질환의치료에유용한화합물
FI932502A (fi) Anordning och foerfarande foer foerflyttning av en maolbaerande solid genomen vaetska foer detektering medan vaetskan haolls i en behaollare
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
FI942643A0 (fi) Menetelmä ja laite biosähköisten virtalähteiden dedusoimiseksi
FI990171A0 (fi) Uusia yhdisteitä ja koostumuksia tryptaasiaktiivisuuden liittyvien tautien hoitamiseksi
FI940509A (fi) Menetelmä normaalin ja ultrahienon sementin valmistamiseksi
FI962370A0 (fi) Laite tissuen valmistamiseksi
FI971750A (fi) Koostumuksia multippeliskleroosia varten ja sen hoito
FI19992807A (fi) Menetelmä ja järjestely häiriön poistamiseksi
FI925327A0 (fi) Foerfarande foer vaord av inflammation och i dessa anvaendbara foereningar och kompositioner
FI962976A0 (fi) Viherkaihin hoitoon tarkoitettuja koostumuksia, jotka sisältävät beta-salpaajaa
FI971138A0 (fi) Keraamisia eristeitä ja menetelmiä niiden muodostamiseksi
FI945945A0 (fi) Foerfarande och anordning foer uppslamning av finfoerdelade aemnen i vaetska
FI943213A (fi) Prosessi valmistaa 3-asyyliestratrieenejä ja asyylibentseenejä
FI972694A0 (fi) Uusi menetelmä sameridiinin valmistamiseksi
AU8049098A (en) Composition and methods for the treatment of inflammatory diseases
FI970713A (fi) Menetelmiä hampaiden ja suun luuston kunnon ylläpitämiseksi
FI951441A0 (fi) Menetelmä 5-formyyliamino-pyrimidiinien valmistamiseksi
FI944183A0 (fi) TDMA-mottagare och foerfarande foer styrning av TDMA-mottagare